Biohaven Ltd. cotiza a 11.42 USD y tiene una capitalización bursátil de $1.7B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in P…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.78 | $-0.69 | $-0.90 |
| Estimado | $0.16 | $-0.61 | $-0.76 | $-0.96 |
| Sorpresa | — | -27.9% | +9.2% | +6.2% |
| Métrica | BHVN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -1418.8% | -40.4% | -1378.4% |
| ROA | -163.7% | -32.0% | -131.7% |
| Current Ratio | 3.18 | 2.84 | +0.34 |
| Debt / Equity | 4.59 | 0.28 | +4.31 |